Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors (GIST) treated with imatinib

Piotr Rutkowski; Paweł Teterycz; Anna Klimczak; Elżbieta Bylina; Katarzyna Szamotulska; I. Ługowska

doi:10.1093/annonc/mdx675

ScienceGate Book Chapters

JOURNAL ARTICLE

Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors (GIST) treated with imatinib

Piotr Rutkowski Paweł Teterycz Anna Klimczak Elżbieta Bylina Katarzyna Szamotulska I. Ługowska

Year: 2017 Journal: Annals of Oncology Vol: 28 Pages: x149-x149 Publisher: Elsevier BV

DOI: 10.1093/annonc/mdx675

Get Full-Text PDF Get Analytical Report

Keywords:

Medicine GiST Internal medicine Imatinib Gastroenterology Proportional hazards model Imatinib mesylate Neutrophil to lymphocyte ratio Stromal tumor Oncology Log-rank test Lymphocyte Stromal cell

Metrics

Cited By

0.00

FWCI (Field Weighted Citation Impact)

Refs

0.25

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Topics

Gastrointestinal Tumor Research and Treatment

Health Sciences → Medicine → Gastroenterology

Inflammatory Biomarkers in Disease Prognosis

Health Sciences → Medicine → Oncology

Metastasis and carcinoma case studies

Health Sciences → Medicine → Pulmonary and Respiratory Medicine

Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors (GIST) treated with imatinib

Metrics

Topics

Related Documents

Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib

The prognostic value of blood neutrophil-to-lymphocyte ratio (NLR) factor in advanced gastrointestinal stromal tumors (GIST) treated with sunitinib after imatinib failure.

Predictive ability of blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in gastrointestinal stromal tumors (GIST).

Relationship of preoperative neutrophil lymphocyte ratio with prognosis in gastrointestinal stromal tumors

Prognostic value of the pretreatment neutrophil‑to‑lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure